Alphatec (ATEC) Q2 2026 Earnings Call Transcript
Alphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the combination of Q2 performance, raised FY adjusted EBITDA guidance, reaffirmed revenue and FCF targets, and management’s stated reason for revenue-per-procedure softness.
Market read
ATEC’s earnings call provides concrete guidance changes (raised FY adjusted EBITDA) and a specific operational explanation for weaker revenue per case, which can drive estimate revisions and positioning.
What to watch
Investors may underweight the cash conversion nuance: free cash flow was near break-even in the quarter ($1M) despite positive trailing-12-month FCF, so execution on inventory investment and set/instrument spend into 2H matters.
Background
The piece is a transcript of Alphatec’s Q2 2026 earnings call, covering operating metrics, guidance, and management commentary on drivers like surgeon adoption, EOS Insight informatics, and biologics attachment.
Ticker impact
Alphatec reported Q2 2026 results and reaffirmed FY revenue guidance, while raising FY adjusted EBITDA guidance and discussing biologics attachment softness.
Near-term bias depends on whether investors focus more on raised FY adjusted EBITDA guidance and positive FCF trend versus the biologics attachment drag on revenue per case.
The article provides multiple decision-relevant datapoints: Q2 revenue and margin expansion, raised FY adjusted EBITDA guidance, reaffirmed revenue and FCF targets, and an explicit management explanation for revenue-per-procedure weakness tied to biologics attachment.
Market effects
Spine procedural and device-adjacent names may see read-through on how informatics adoption (EOS Insight) and biologics attachment dynamics affect utilization and monetization.
International expansion commentary (Japan, Australia, New Zealand) could influence sentiment toward growth outside the US for similar spine platforms.
If EOS Insight adoption scales internationally as described, it supports the broader thesis that procedural informatics can lift implant revenue across geographies.
Counterpoint
The raised adjusted EBITDA guidance may be partially offset by continued biologics attachment stagnation, implying revenue per case could remain a ceiling even if case volumes rise.
Key entities
- companyAlphatec Holdings
ATEC, reported Q2 2026 revenue growth, margin expansion, and guidance updates, with biologics attachment cited as a key constraint on revenue per case.
- productEOS Insight
Cloud-based informatics platform; management cited adoption growth and revenue lift at established accounts.
- productValence
Interoperative navigation system; management said it received FDA clearance for interoperative alignment (IOA).
